The 700,000-square-foot plant in Holly Springs will create more than 400 jobs and support Roche and Genentech’s future portfolio of next-generation obesity medicines.
The Xcell-Eng-HEK293 cell line is designed to improve the scalability and consistency of recombinant AAV (rAAV) production for cell and gene therapy applications.
The new site will enable Ratio to vertically integrate its pipeline of radiopharmaceuticals for cancer treatment and monitoring, with capabilities for end-to-end production.
The order falls under a 10-year contract with the Biomedical Advanced Research and Development Authority (BARDA), which includes additional options totaling $299 million.
The Danish drugmaker said the decision followed an extensive evaluation of operational challenges, including cost pressures and ongoing market constraints.
To achieve greater efficiency, BMS is optimizing its manufacturing footprint and shifting work from Libertyville near Chicago to a facility in Devens, Massachusetts.
The expansion at its King of Prussia, Pennsylvania facility adds critical capacity for high-quality plasmid production at a key U.S. biomanufacturing site.
CEO Christopher Viehbacher told analysts that a significant proportion of U.S. revenue is derived from products which have domestic manufacturing operations in the country.
The approval enables pharma& to begin product replenishment across Europe following its 2021 acquisition of global rights to Pegasys from F. Hoffmann-La Roche.
CEO Pascal Soriot said that the company has 11 manufacturing sites in the U.S. which could help mitigate potential tariffs on pharmaceuticals by the Trump administration.
The companies are offering biomanufacturers a full suite of cell line development and cell culture services to accelerate the production of protein biologics.
CEO Vas Narasimhan acknowledged the company “could have done this earlier” but insisted it was a “strategic decision independent of the President” of the United States.
The company said it is growing both its total reactor volume of small molecule APIs and total reactor volume of solid phase peptide synthesizers by the end of 2025.
Ferring Pharmaceuticals has expanded Adstiladrin production with a new facility in Parsippany, New Jersey, adding to existing sites in Kuopio, Finland.
